allogeneic haploidentical stem cell transplantation in childrenunmanipulated haploidentical stem cell transplantationposttransplant Cyаллогенная трансплантация от гаплоидентичного донора у детейнеманипулированные ГСК от гаплоидентичного донорапосттрансплантационный циклофосфан1.Lucchini G., Labopin M., Beohou E., Dalissier A., Dalle J.H., Cornish J., Zecca M., et al. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2017; 23 (3): 467-74.2.Bashey A., Solomon S.R. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplantation 2014; 49: 999-1008.3.Алянский А.Л., Кучер М.А., Макаренко О.А., Головачева А.А., Кузмич Е.В., Бабенко Е.В., Эстрина М.А. и др. Актуальные вопросы поиска неродственного донора костного мозга в Российскрй Федерации. Трансфузиология 2016; 3: 21-8.4.Santoro N., Ruggeri A., Labopin M., Bacigalupo A., Ciceri F., Gulbas Z., Huang H., et al. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol 2017; 10 (1): 113-24.5.Семенова Е.В., Станчева Н.В., Алянский А.Л., Бабенко Е.В., Вавилов В.Н., Морозова Е.В., Бондаренко С.Н. и др. Аллогенная трансплантация гемопоэтических клеток с режимами кондиционирования со сниженной ин-тенсивностью доз у дететй и подростков с прогностически неблагоприятными формами острого лимфобластного лей-коза. Онкогематология 2011; 4: 25-32.6.BitanM., HeW., ZhangM.-J., AbdelAzimH., AyasM.F., BieloraiB., CarpenterP.A., etal. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood 2014; 123 (10): 1615-20.7.Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematological malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012;18 :1859-66.8.Anasetti C., Beatty P.G., Storb R., Martin P.J., Mori M., Sanders J.E., et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990; 29: 79-91.9.Beatty P.G., Clift R.A., Mickelson E.M., Nisperos B.B., Flournoy N., Martin P.J., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-71.10.Powles R.L., Morgenstern G.R., Kay H.E., McElwain T.J., Clink H.M., Dady P.J., et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983; 1: 612-5.11.Szydlo R., Goldman J.M., Klein J.P., Gale R.P., Ash R.C., Bach F.H., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767-77.12.Aversa F., Terenzi A., Tabilio A., Falze-tti F., Carotti A., Ballanti S., et al. Full haplotype mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-54.13.Huang X.J., Liu D.H., Liu K.Y., Xu L.P., Chen H., Han W., Chen Y.H., Zhang X.H., Lu D.P. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15: 257-65.14.Berenbaum M.C., Brown I.N. Prolongation of Homograft Survival in Mice with Single Doses of Cyclophosphamide. Nature 1963; 200: 84.15.Kekre N., Antin J.H. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 2014; 123 (3): 334-43.16.Moiseev I.S., Pirogova O.V., Alyanski A.L., Babenko E.V., Gindina T.L., Darskaya E.I., Slesarchuk O.A., et al. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus and Mycophenalate Mofetil. BiolBloodMarrowTransplant 2016; 22 (6): 1037-42.17.Масчан М.А. Деплеция альфа/бета-Т-лимфоцитов - надежная платформа для развития трансплантации гемопоэтических стволовых клеток от гаплоидентичных доноров. Российский журнал детской гематологии и онкологии 2015; 2 (3): 34-8.18.ZeccaM., StrocchioL., PagliaraD., ComoliP., BertainaA., GiorgianiG., PerottiC., etal. HLA-haploidentical T-cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. Biol Blood Marrow Transplant 2014; 20 (4): 571-6.19.Wang Z., Zheng X., Yan H., Li D., Wang H. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia. Bone Marrow Transplantation 2014; 49: 1481-5.20.Huang X.-J. Current status of haploidentical stem cell transplantation for leukemia. Journal of Hematology & Oncology 2008; 1: 27-36.21.Wang Y., Chang Y.-J., Xu L.-P., Liu K.-Y., Liu D.-H., Zhang X.-H., Chen H., et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 2014; 124: 843-50.22.Luznik L., O’Donnell P.V., Symons H.J., Chen A.R., Leffell M.S., Zahurak M., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post transplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641-50.23.Ciurea S.O., Mulanovich V., Saliba R.M., Bayraktar U.D., Jiang Y., Bassett R., Wang S.A., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 2012; 18: 1835-44.